Key Takeaways
- Isomorphic Labs secured a $2.1 billion Series B round, led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG and the U.K. government’s AI fund.
- The funding follows a $600 million external round a year earlier, bringing total external capital to over $2.7 billion.
- The company’s AI drug‑design engine, IsoDDE, leverages models like AlphaFold 3 to predict molecular structures and interactions.
- Proceeds will scale IsoDDE, advance the in‑house pipeline toward clinical trials, and expand partnerships with pharma giants such as Eli Lilly and Novartis.
- Founder Demis Hassabis describes the round as a “massive vote of confidence” that will enable the firm to “solve all disease” through AI‑first drug discovery.
- Alphabet’s President and CIO Ruth Porat praised the progress, noting the funding will accelerate bringing important interventions to market.
Massive Funding Signals Continued Investor Appetite for AI‑Driven Drug Discovery
If any proof was needed that big money is still available for AI drug development, look no further than the ten‑figure Series B hauled in by Isomorphic Labs. The London‑based AI drug discovery firm, founded by Alphabet in 2021, announced a $2.1 billion round led by Thrive Capital, with Alphabet and its venture arm GV joining as existing backers. New investors included MGX, Temasek, CapitalG and the United Kingdom government’s AI fund. This influx of capital follows a $600 million external financing round a year earlier, pushing the company’s total external funding well beyond $2.7 billion. The scale of the investment underscores confidence that AI can reshape the traditionally lengthy and costly drug discovery pipeline.
Isomorphic’s Vision: A Unified AI Drug Design Engine
Isomorphic was created with a clear mission: to develop a suite of AI models that together form a unified drug design engine. The firm’s proprietary platform, dubbed IsoDDE (Isomorphic Drug Design Engine), integrates several cutting‑edge models, most notably AlphaFold 3—a collaboration between Google DeepMind and Isomorphic that predicts the three‑dimensional structures of proteins and their interactions with small molecules. By combining structure prediction with generative chemistry and predictive toxicology modules, IsoDDE aims to identify promising drug candidates far more rapidly than conventional methods. The new capital will be directed toward expanding the engine’s computational infrastructure, refining its algorithms, and deploying it across multiple therapeutic areas.
Strategic Partnerships Validate the Technology
The company’s approach has already attracted interest from major pharmaceutical players. IsoDDE‑driven projects have resulted in deals with Eli Lilly and Novartis, both of which tasked Isomorphic with using AlphaFold 3 to discover small molecules for undisclosed targets. These collaborations serve as external validation that the AI‑generated hypotheses are chemically tractable and biologically relevant. While the specifics of the targets remain confidential, the fact that two of the world’s largest drug makers are allocating resources to Isomorphic’s platform signals a strong belief in its predictive power and potential to reduce early‑stage failure rates.
Founder’s Perspective: Scaling Toward a Disease‑Solving Mission
Demis Hassabis, founder and CEO of Isomorphic Labs, framed the Series B as a pivotal step toward the company’s overarching ambition. In a press release dated May 12, he stated, “This funding round is a massive vote of confidence from a diverse group of top‑tier international investors in our AI‑first approach to drug design and development.” He added, “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential.” Hassabis went on to articulate the broader vision, quoting himself as saying the round “allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.” The language reflects both optimism and a clear roadmap: move from proof‑of‑concept to industrial‑scale AI‑driven drug creation.
Alphabet’s Endorsement Highlights Strategic Alignment
Ruth Porat, President and Chief Investment Officer of Alphabet and Google, also weighed in on the financing, reinforcing the strategic fit between Isomorphic and its parent conglomerate. She remarked, “Isomorphic has already made extraordinary progress in harnessing AI to accelerate drug discovery.” Porat continued, “This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed.” Her comments highlight that Alphabet views Isomorphic not merely as a financial investment but as a core component of its broader AI‑for‑good initiatives, leveraging DeepMind’s breakthroughs in structural biology to address unmet medical needs.
Looking Ahead: From Engine to Clinic
The immediate plan for the freshly raised capital is twofold. First, Isomorphic will scale IsoDDE to handle larger libraries of chemical space and more complex biological targets, increasing throughput and predictive accuracy. Second, the company intends to advance its internal drug pipeline toward preclinical and clinical stages, translating AI‑generated candidates into tangible therapeutic candidates. By coupling robust AI models with rigorous experimental validation, Isomorphic hopes to compress the typical decade‑long drug development timeline and lower the associated costs—a proposition that has attracted both venture and sovereign investors alike.
Conclusion: A Watershed Moment for AI‑Enabled Pharma
The $2.1 billion Series B round marks a watershed moment for AI‑enabled pharmaceutical innovation. It demonstrates that, despite macroeconomic headwinds, deep‑pocketed investors remain willing to back ambitious AI platforms that promise to reinvent drug discovery. With strong backing from Alphabet, a cadre of global institutional investors, and validated partnerships with pharma titans, Isomorphic Labs is positioned to push the boundaries of what AI can achieve in medicine. As Hassabis succinctly put it, the goal is nothing less than to “solve all disease.” Whether that lofty ambition is fully realized remains to be seen, but the current financing trajectory suggests the industry is betting heavily on AI’s potential to deliver.
https://www.fiercebiotech.com/biotech/alphabets-ai-biotech-isomorphic-labs-bags-21b-series-b-fuel-next-gen-drug-design-model